Research Article
BibTex RIS Cite

MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU

Year 2018, Volume: 19 Issue: 3, 79 - 81, 23.07.2018
https://doi.org/10.18229/kocatepetip.345682

Abstract

AMAÇ: Memenin taşlı yüzük hücreli karsinomu agresif klinik
gidişatı olan nadir bir alt gruptur. Meme kanserlerinin %2-4.5’ini oluştururlar.
Bu çalışmada taşlı yüzük hücreli meme kanseri olgularının klinik ve patolojik
özelliklerini analiz ettik.

GEREÇ VE
YÖNTEM:
2007-2014 tarihleri arasında Hacettepe Üniversitesi
Kanser Enstitüsü’nde meme kanseri tanısı alan ve tedavi edilen 3587 hastaya ait
veriler incelendi. Hastaların demografik özellikleri ve patoloji raporları,
klinik sonuçlarla birlikte değerlendirildi.

BULGULAR: Taşlı yüzük hücreli meme karsinomu olan 25 hasta
bulundu (%1). Ortanca yaşları 53 olan bu hasta grubunun %48’i premenapozal
dönemde tanı almıştı. Tanı anında 4 hastanın metastatik, diğer 21 hastanın ise
lokal hastalığı vardı.  Tümörler genellikle grade 2, ER pozitif ve HER2 negatif
idi. Mikst histoloji tespit edilen hastalardan 9’unda invaziv duktal karsinom,
6’sında invaziv lobüler karsinom eşlik etmekteydi. Ortalama takip süresi 27 ay
idi. Yedi hastada nüks gözlendi (1 lokal, 1 hem lokal hem uzak, 5 uzak). Kemik,
karaciğer ve overler en sık uzak nüks saptanan organlar idi (sırasıyla 3, 2 ve
2).







SONUÇ: Bu çalışmada, taşlı yüzük hücreli meme karsinomu
prevalansı literatürden daha düşük olarak bulunmuştur (%0.7). İnvaziv duktal
karsinom en sık eşlik eden tiptir. Uzak nüksü olan 7 hastadan 2’sinde tutulan
organ overdir. Taşlı yüzük hücreli karsinom olgularında over metastazı ile
karşılaşılabilir.

References

  • 1. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. The American journal of surgical pathology 2000;24:1650-1656.
  • 2. Steinbrecher JS, Silverberg SG. Signet-ring cell carcinoma of the breast. The mucinous variant of infiltrating lobular carcinoma? Cancer 1976;37:828-840.
  • 3. Merino MJ, Livolsi VA. Signet ring carcinoma of the female breast: a clinicopathologic analysis of 24 cases. Cancer 1981;48:1830-1837.
  • 4. Hull MT, Seo IS, Battersby JS, Csicsko JF. Signet-ring cell carcinoma of the breast: a clinicopathologic study of 24 cases. American journal of clinical pathology 1980;73:31-35.
  • 5. Wu X, Zhang Z, Li X, et al. Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous Carcinoma. PloS one 2016;11:e0162088.
  • 6. Liu SM, Chen DR. Signet-ring cell carcinoma of the breast. Pathology international 2000;50:67-70.
  • 7. Kondo Y, Akita T, Sugano I, Isono K. Signet ring cell carcinoma of the breast. Acta pathologica japonica 1984;34:875-880.
  • 8. Koos L, Field RE. Metastatic carcinoma of breast simulating Crohn's disease. International surgery 1980;65:359-362.

SIGNET RING CELL CARCINOMA OF BREAST

Year 2018, Volume: 19 Issue: 3, 79 - 81, 23.07.2018
https://doi.org/10.18229/kocatepetip.345682

Abstract

OBJECTIVE: Signet ring cell carcinoma
(SRCC) of breast is a rare subtype with aggressive clinical course. The
prevalence of signet ring features is between 2 to 4.5% of total breast
cancers. Here we analyzed clinical and pathological features and outcomes of
our patients with SRCC of breast.

MATERIALS AND
METHODS:
We investigated
retrospectively medical charts of 3587 patients with breast cancer diagnosed
and treated in Hacettepe University Cancer Institute between 2007-2014. Patient
demographics, pathology reports were assessed along with clinical outcomes.

RESULTS: Twenty five patients with
SRCC were identified (1%) Median age was 53 years and 48% of them were
premenopausal. At initial diagnosis, metastatic disease was seen in 4 patients,
other 21 patients have localized disease. Tumors were mostly grade 2, ER
positive and Her2 negative. In patients with mixed histology, co-existed
histology was invasive ductal carcinoma in 9 patients and invasive lobular
carcinoma in 6 patients.  Median follow
up was 27 months. Seven patients had recurrence (1 local, 1 both local and
distant, 5 distant). Most common site of distant relapses were bone, liver and
ovaries (3, 2 and 2 patients, respectively).







CONCLUSION: In this study, the prevalence of
SRCC was found 0.7 %, which is lower than that reported in the literature.
Invazive ductal carcinoma is the most common accompanying subtype. Ovarian
metastases were found in 2 of 7 distant failures. Signet ring cell histology
may have a predilection for ovarian metastases.

References

  • 1. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. The American journal of surgical pathology 2000;24:1650-1656.
  • 2. Steinbrecher JS, Silverberg SG. Signet-ring cell carcinoma of the breast. The mucinous variant of infiltrating lobular carcinoma? Cancer 1976;37:828-840.
  • 3. Merino MJ, Livolsi VA. Signet ring carcinoma of the female breast: a clinicopathologic analysis of 24 cases. Cancer 1981;48:1830-1837.
  • 4. Hull MT, Seo IS, Battersby JS, Csicsko JF. Signet-ring cell carcinoma of the breast: a clinicopathologic study of 24 cases. American journal of clinical pathology 1980;73:31-35.
  • 5. Wu X, Zhang Z, Li X, et al. Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous Carcinoma. PloS one 2016;11:e0162088.
  • 6. Liu SM, Chen DR. Signet-ring cell carcinoma of the breast. Pathology international 2000;50:67-70.
  • 7. Kondo Y, Akita T, Sugano I, Isono K. Signet ring cell carcinoma of the breast. Acta pathologica japonica 1984;34:875-880.
  • 8. Koos L, Field RE. Metastatic carcinoma of breast simulating Crohn's disease. International surgery 1980;65:359-362.
There are 8 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Articles
Authors

Serkan Akın

Publication Date July 23, 2018
Acceptance Date November 20, 2017
Published in Issue Year 2018 Volume: 19 Issue: 3

Cite

APA Akın, S. (2018). MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU. Kocatepe Tıp Dergisi, 19(3), 79-81. https://doi.org/10.18229/kocatepetip.345682
AMA Akın S. MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU. KTD. July 2018;19(3):79-81. doi:10.18229/kocatepetip.345682
Chicago Akın, Serkan. “MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU”. Kocatepe Tıp Dergisi 19, no. 3 (July 2018): 79-81. https://doi.org/10.18229/kocatepetip.345682.
EndNote Akın S (July 1, 2018) MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU. Kocatepe Tıp Dergisi 19 3 79–81.
IEEE S. Akın, “MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU”, KTD, vol. 19, no. 3, pp. 79–81, 2018, doi: 10.18229/kocatepetip.345682.
ISNAD Akın, Serkan. “MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU”. Kocatepe Tıp Dergisi 19/3 (July 2018), 79-81. https://doi.org/10.18229/kocatepetip.345682.
JAMA Akın S. MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU. KTD. 2018;19:79–81.
MLA Akın, Serkan. “MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU”. Kocatepe Tıp Dergisi, vol. 19, no. 3, 2018, pp. 79-81, doi:10.18229/kocatepetip.345682.
Vancouver Akın S. MEMENİN TAŞLI YÜZÜK HÜCRELİ KARSİNOMU. KTD. 2018;19(3):79-81.

88x31.png
Bu Dergi Creative Commons Atıf-GayriTicari-AynıLisanslaPaylaş 4.0 Uluslararası Lisansı ile lisanslanmıştır.